These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? Siegelin MD Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257 [TBL] [Abstract][Full Text] [Related]
5. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors. Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000 [TBL] [Abstract][Full Text] [Related]
6. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Smith JR; Workman P Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013 [TBL] [Abstract][Full Text] [Related]
7. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899 [TBL] [Abstract][Full Text] [Related]
8. Targeting Hsp90 in urothelial carcinoma. Chehab M; Caza T; Skotnicki K; Landas S; Bratslavsky G; Mollapour M; Bourboulia D Oncotarget; 2015 Apr; 6(11):8454-73. PubMed ID: 25909217 [TBL] [Abstract][Full Text] [Related]
9. Hsp90 as a "Chaperone" of the Epigenome: Insights and Opportunities for Cancer Therapy. Isaacs JS Adv Cancer Res; 2016; 129():107-40. PubMed ID: 26916003 [TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90: the cancer chaperone. Neckers L J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171 [TBL] [Abstract][Full Text] [Related]
11. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy. Ren X; Li T; Zhang W; Yang X Cells; 2022 Aug; 11(16):. PubMed ID: 36010632 [TBL] [Abstract][Full Text] [Related]
12. Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions. Wang M; Shen A; Zhang C; Song Z; Ai J; Liu H; Sun L; Ding J; Geng M; Zhang A J Med Chem; 2016 Jun; 59(12):5563-86. PubMed ID: 26844689 [TBL] [Abstract][Full Text] [Related]
13. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. Wang L; Zhang Q; You Q Med Res Rev; 2022 Jan; 42(1):156-182. PubMed ID: 33846988 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Sreedhar AS; Soti C; Csermely P Biochim Biophys Acta; 2004 Mar; 1697(1-2):233-42. PubMed ID: 15023364 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. Pines G; Köstler WJ; Yarden Y FEBS Lett; 2010 Jun; 584(12):2699-706. PubMed ID: 20388509 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Koga F; Kihara K; Neckers L Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312 [TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220 [TBL] [Abstract][Full Text] [Related]
19. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Georgakis GV; Younes A Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999 [TBL] [Abstract][Full Text] [Related]
20. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Workman P; Burrows F; Neckers L; Rosen N Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]